<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335591">
  <stage>Registered</stage>
  <submitdate>7/06/2010</submitdate>
  <approvaldate>10/06/2010</approvaldate>
  <actrnumber>ACTRN12610000477022</actrnumber>
  <trial_identification>
    <studytitle>Comparison of Inflammation, Oxidative Stress, and Respiratory Outcomes Between Conventional and Protective One Lung Ventilation in Patients Undergoing Lung Resection Surgery</studytitle>
    <scientifictitle>Comparison of Inflammation, Oxidative Stress, and Respiratory Outcomes Between Conventional and Protective One Lung Ventilation in Patients Undergoing Lung Resection Surgery for Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>lung cancer</healthcondition>
    <healthcondition>lung lobectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Protective One Lung Ventilation (tidal volume 6 ml/kg, 5cmH2O positive end-expiratory pressure, inspiratory oxygen partial pressure:FiO2 0.5) / continuously applied during lobectomy (approximately 60-90 minutes).</interventions>
    <comparator>Conventional One Lung Ventilation (tidal volume 10 ml/kg, 0 cmH2O positive end-expiratory pressure, FiO2 1.0 / continuously applied during lobectomy (approximately 60-90 minutes).</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>respiratory parameters(airway pressure, tidal volume, inspiratory oxygen partial pressure:FiO2, respiratory rate) measured by pneumotachometer</outcome>
      <timepoint>baseline = baseline time after anesthetic induction and before ventilation strategy application; OLV 15 and OLV 60 = 15 minutes and 60 minutes after initiation of OLV, respectively; two lung ventilation(TLV) 15 = 15 minutes after the end of OLV</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>arterial blood gas analysis: arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbondioxide (PaCO2), pH</outcome>
      <timepoint>baseline = baseline time after anesthetic induction and before ventilation strategy application; OLV 15 and OLV 60 = 15 minutes and 60 minutes after initiation of OLV, respectively; TLV 15 = 15 minutes after the end of OLV</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>blood interleukin 6</outcome>
      <timepoint>baseline = baseline time after anesthetic induction and before ventilation strategy application; OLV 60 = 60 minutes after initiation of OLV; TLV 15 = 15 minutes after the end of OLV</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>blood malondialdehyde</outcome>
      <timepoint>baseline = baseline time after anesthetic induction and before ventilation strategy application; OLV 60 = 60 minutes after initiation of OLV; TLV 15 = 15 minutes after the end of OLV</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>hospital stay through data linkage to patient medical records</outcome>
      <timepoint>when patients' discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>chest radiograph</outcome>
      <timepoint>every day for 1 week postoperatively</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>American Society  of Anesthesiologist (ASA) physical status 1-2 and scheduled for an elective video-assisted thoracoscopic (VATS) lobectomy due to lung cancer</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>patients refusal to take part in the study, coexisting chronic obstructive lung disease with forced expiratory volume in 1 s of less than 80% of predicted and/or forced expiratory volume in 1 s over forced vital capacity ratio of less than 0.7, chronic renal failure, altered liver function, preoperative corticosteroid treatment during one month before operation, elevated temperature or leukocyte count, or any new pulmonary infiltration on the chest radiography (CXR).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/08/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Jie Ae Kim</primarysponsorname>
    <primarysponsoraddress>Department of anesthesiology and pain medicine. Samsung Medical Center, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</primarysponsoraddress>
    <primarysponsorcountry>Korea, Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Samsung Medical Center Clinical Research Development Program grant, CRS110-07-1</fundingname>
      <fundingaddress>50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</fundingaddress>
      <fundingcountry>Korea, Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Hyun Joo Ahn</sponsorname>
      <sponsoraddress>Department of anesthesiology and pain medicine. Samsung Medical Center, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</sponsoraddress>
      <sponsorcountry>Korea, Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study compared inflammatory and oxidative stress, and respiratory outcomes between conventional and protective OLV in patients with normal lung function undergoing video-assisted thoracoscopic (VATS) lobectomy due to lung cancer.  
Fifty ASA 1-2 patients undergoing elective VATS lobectomy were randomly assigned into conventional (CV: tidal volume 10 ml/kg, FiO2 1.0, zero positive end-expiratory pressure under volume-controlled ventilation) or protective (PV: tidal volume 6 ml/kg, FiO2 0.5, positive end-expiratory pressure 5 cmH2O under pressure-controlled ventilation) OLV group. Respiratory parameters, arterial blood gases, blood malondialdehyde (MDA) and interleukin 6 (IL 6) were analyzed at baseline, 15 min and 60 min after OLV (OLV 15 and OLV 60, respectively), and 15 min after the restoration of two lung ventilation (TLV 15). Postoperative chest radiography (CXR) and respiratory outcomes were also evaluated.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional review board</ethicname>
      <ethicaddress>50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</ethicaddress>
      <ethicapprovaldate>7/02/2009</ethicapprovaldate>
      <hrec>2009-01-043-001</hrec>
      <ethicsubmitdate>3/01/2009</ethicsubmitdate>
      <ethiccountry>Korea, Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jie Ae Kim</name>
      <address>Department of anesthesiology and pain medicine. Samsung Medical Center, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</address>
      <phone>82-2-3410-0363</phone>
      <fax />
      <email>jakim0813@yahoo.com</email>
      <country>Korea, Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jie Ae Kim</name>
      <address>Department of anesthesiology and pain medicine. Samsung Medical Center, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</address>
      <phone>82-2-3410-0363</phone>
      <fax />
      <email>jakim0813@yahoo.com</email>
      <country>Korea, Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jie Ae Kim</name>
      <address>Department of anesthesiology and pain medicine. Samsung Medical Center, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea</address>
      <phone>82-2-3410-0363</phone>
      <fax />
      <email>jakim0813@yahoo.com</email>
      <country>Korea, Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>